Saturday, June 10th

Efficacy and Safety of Liraglutide in Insulin-Pump-Treated People with Type 1 Diabetes: The Lira Pump Trial Thomas F. Dejgaard, MD - Steno Diabetes Center Copenhagen

Twenty-Four-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes (inTandem1) John B. Buse, MD, PhD - University of North Carolina School of Medicine

A Decrease In Insulin Action, But Not In ß-Cell Function, Impairs Glucagon Suppression In Nondiabetic Humans Ron T. Varghese MBBS - Mayo Clinic

Metabolism, In Vivo (Animals) Beta-Cell Sensitivity To Incretin Infusions In Healthy Adults Mark D. Miller MD - Duke University Medical System

Friday, June 9th

CGM Outcomes―How Current Recommendations Regarding Time in Range, Hypoglycemia, Hyperglycemia, Glucose Variability, and Glucose Pattern Visualization Agree and Differ Richard Bergenstal, MD - International Diabetes Center

Key Issues in Adopting and Implementing Standardized CGM Outcome Metrics Simon R. Heller, FRCP, DM - University Of Sheffield

Sunday, June 11th

SGLT2 Inhibitors2 David Cherney, MD, CM, PhD, FRCP(C) - University Of Toronto

GLP-1 Receptor Agonists Katherine R. Tuttle, MD, FACP, FASN, FNKF - University Of Washington School Of Medicine

DPP-4 Inhibitors Mark Emmanuel Cooper, MBBS, PhD - Monash University

Monday, June 12th

Nasal Glucagon for the Treatment of Moderate-to-Severe Hypoglycemic Episodes in Real-World Settings in Adults with Type 1 Diabetes Elizabeth R. Seaquist, MD University of Minnesota